DIAGNOSIS OF ANXIETY AND DEPRESSION IN MOTOR NEURON DISEASE WITH CLINICAL-NEUROLOGICAL METHODS
DOI:
https://doi.org/10.55640/Keywords:
Motor neuron disease, amyotrophic lateral sclerosis, degenerative processes, anxiety, depression.Abstract
Motor neuron disease according to ICD-10 belongs to the class of diseases with systemic atrophy of the elements of the central nervous system. Motor neuron disease (MND) is also called amyotrophic lateral sclerosis (ALS). This disease is characterized by damage to the upper neurons of the brain with subsequent disruption of their connection with the spinal cord. As a result of the disease, paralysis of the whole body develops.
Downloads
References
1.Abati E., Bresolin N., Comi G., Corti S. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS). // Expert Opin Ther Targets. – 2020; 24 (4): 295–310.
2.Agah E., Saleh F., Sanjari Moghaddam H., et al. CSF and blood biomarkers in amyotrophic lateral sclerosis: protocol for a systematic review and meta-analysis // Syst. Rev. – 2018; 7: 237.
3.Akaishi T., Tateyama M., Kato K., et al. An autopsy case involving a 12-year history of amyotrophic lateral sclerosis with CIDP-like polyneuropathy // Intern Med. – 2014; 53(12): 1371–1375.
4.Al-Chalabi, A. Amyotrophic lateral sclerosis: moving towards a new classification system / A. Al-Chalabi, O. Hardiman, M.C. Kiernan // Lancet Neurol. – 2016. – Vol. 15. – № 11. – rr. 1182–1194.
5.Andrew A.S., Pioro E.P., Li M., et al. The incidence of amyotrophic lateral sclerosis in Ohio 2016–2018: the Ohio population-based ALS registry // Neuroepidemiology. – 2021; 55(3): 196–205.
6.Antao V.C., Horton D.K. The National Amyotrophic Lateral Sclerosis (ALS) Registry // Journal Environ Health. – 2012; 75: 28–30.
7.Antonescu F., Adam M., Popa C., Tuţă S. A review of cervical spine MRI in ALS patients // Journal Med. Life. – 2018; 11 (2): 123–127.
8.Axel F., Thomas W., Benjamin R., Wolfgang R. Haplo insufficiency of TBK1 causes familial ALS and fronto-temporal dementia // Nature Neuroscience. – 2015.
9.Bä umer D., Talbot K., Turner M.R. Advances in motor neurone disease // J R Soc Med. – 2014 Jan; 107(1): 14-21. DOI:10.1177/0141076813511451.
10.Bandres-Ciga S., Noyce A.J., Hemani G., et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis // Ann Neurol. – 2019. 85(4): 470–481.
11.Bedlack R.S., Vaughan T., Wicks P., Heywood J., et al. How common are ALS plateaus and reversals? // Neurology. – 2016; 86: 808–812.
12.Bello-Haas V.D. Physical therapy for individuals with amyotrophic lateral sclerosis: current insights // Degener Neurol Neuromuscul Dis. – 2018; 8: 45–54.
13.Benbrika S., Desgranges B., Eustache F., Viader F. Cognitive, Emotional and Psychological Manifestations in Amyotrophic Lateral Sclerosis at Baseline and Overtime: A Review // Front Neurosci. – 2019; 13: 951.
14.Bhandari R., Kuhad A., Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis // Drugs Today (Barc). – 2018; 54: 349–60.
15.Bledsoe M.J., Rechtman L., Wagner L., Mehta, et al. Analysis of biospecimen demand and utilization of samples from the National Amyotrophic Lateral Sclerosis Biorepository // Biopreserv Biobanking. – 2021; 19(5): 432–437.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India
